Search company, investor...

Founded Year



Series A | Alive

Total Raised


Last Raised

$18M | 2 yrs ago

About Cordio

Cordio operates as a company focusing on healthcare technology. It provides medical-grade solutions to monitor health conditions by analyzing voice samples recorded in a simple smartphone application, which allows for near real-time monitoring and early detection of condition deterioration. The company primarily serves the healthcare industry. It was founded in 2013 and is based in Or Yehuda, Israel.

Headquarters Location

6 Yehonatan Netanyahu Street

Or Yehuda, 6037604,




ESPs containing Cordio

The ESP matrix leverages data and analyst insight to identify and rank leading companies in a given technology landscape.

Healthcare & Life Sciences / Monitoring, Imaging & Diagnostics Tech

The lung health audio biomarkers market focuses on leveraging sound waves to diagnose and monitor pulmonary conditions. These technologies can be used to detect changes in breathing, coughing, and other sounds associated with respiratory disorders. The market aims to address the high cost and time associated with respiratory clinical trials. Additionally, there is a need for more effective ways to…

Cordio named as Outperformer among 9 other companies, including Innovaccer, Verily, and TytoCare.


Expert Collections containing Cordio

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Cordio is included in 2 Expert Collections, including Digital Health.


Digital Health

10,585 items

The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.



2,856 items

Companies developing, offering, or using electronic and telecommunication technologies to facilitate the delivery of health & wellness services from a distance. *Columns updated as regularly as possible; priority given to companies with the most and/or most recent funding.

Cordio Patents

Cordio has filed 21 patents.

The 3 most popular patent topics include:

  • classification algorithms
  • machine learning
  • artificial neural networks
patents chart

Application Date

Grant Date


Related Topics




Machine learning, Classification algorithms, Artificial intelligence, Natural language processing, Artificial neural networks


Application Date


Grant Date



Related Topics

Machine learning, Classification algorithms, Artificial intelligence, Natural language processing, Artificial neural networks



Latest Cordio News

Cordio Medical Presents Study Validating Voice Signature AI Tool that Monitors Congestive Heart Failure

Nov 14, 2023

News Provided By Share This Article Cordio Medical HearO ™ app predicts possible complications in patients with heart failure through speech, detecting the accumulation of fluid related to the disease. NEW YORK, NEW YORK, UNITED STATES, November 14, 2023 / / -- Cordio Medical , developer of the HearO® app, presented the positive results from their clinical study during the American Heart Association's Scientific Sessions . The research tested and validated the HearO® app, which combines the first smartphone-based mobile speech application and cloud-based computing to detect changes in Speech Measures (SM) indicative of worsening heart failure. The Cordio HearO® system demonstrated a remarkable ability to identify patients at risk of worsening heart failure, offering a critical window for timely intervention and treatment. By harnessing the power of AI and speech analysis, this innovative technology has the potential to significantly reduce heart failure events, improve patient outcomes, and usher in a new era of personalized, proactive healthcare. “Worsening heart failure events (HFEs) requiring hospitalization and intravenous therapies represent one of the most pressing medical challenges,” said Tamir Tal, CEO of Cordio Medical. “The ability to predict heart failure events before they occur creates the potential to reduce heart failure events significantly, and by extension, the leading cause of hospitalizations in patients over 65.” The study's objective was to develop and validate a practical user-friendly tool for predicting such events in ambulatory heart failure patients to prevent hospitalization and/or intravenous therapies. In the development group, 76.3% of first and recurrent heart failure events were detected before they occurred, with a similar success rate of 71.4% in the test group. Events were detected approximately 3 weeks in advance, and the unexplained priority notification rate was minimal (1). "Our research marks a pivotal moment in the fight against heart failure,” says Dr. William T. Abraham, College of Medicine Distinguished Professor at The Ohio State University Wexner Medical Center and the study's lead researcher. “With the Cordio HearO® system, we've harnessed the potential of AI to monitor heart failure patients remotely through a person’s unique voice signature and a smartphone. We're not just predicting events; we're providing an opportunity for timely intervention and improved patient outcomes." Cordio HearO® Community Study, a non-interventional, single-arm clinical study, enrolled New York Heart Association Class II and III heart failure outpatients, irrespective of left ventricular ejection fraction. Cordio Medical Cordio Medical develops and provides groundbreaking solutions for monitoring health conditions through a patient's speech. Cordio Medical's technologies are based on true speech signal processing technology, unique to each patient, augmented with machine learning capabilities. We strive to improve patient health quality and mortality while contributing to the advancement of health economics. For more information on Cordio Medical, go to . References: 1) Abraham, W., et al. (2023). Validation of a Speech Analysis Application to Detect Worsening Heart Failure Events in Ambulatory Heart Failure Patients!/10871/presentation/16568 Steven Weiss

Cordio Frequently Asked Questions (FAQ)

  • When was Cordio founded?

    Cordio was founded in 2013.

  • Where is Cordio's headquarters?

    Cordio's headquarters is located at 6 Yehonatan Netanyahu Street, Or Yehuda.

  • What is Cordio's latest funding round?

    Cordio's latest funding round is Series A.

  • How much did Cordio raise?

    Cordio raised a total of $18M.

  • Who are the investors of Cordio?

    Investors of Cordio include Peregrine Ventures, Ceros Capital Markets, BIRD Foundation, Bayer G4A, PlayBeyondBio and 3 more.

  • Who are Cordio's competitors?

    Competitors of Cordio include Donisi Health.


Compare Cordio to Competitors


BioBeat is a medical technology company. Its remote patient monitoring (RPM) health platform includes a disposable short-term chest-monitor and a long-term wrist-monitor, both of which utilize a photoplethysmography-based (PPG) sensor to provide patient readings of various health parameters, including cuffless blood pressure, pulse rate, respiratory rate, blood oxygen saturation, temperature, stroke volume, cardiac output, and more. The company was founded in 2016 and is based in Petach Tikva, Israel.

Sensible Medical Innovations

Sensible Medical Innovations is a company focused on healthcare technology. The company's main offering is a non-invasive system for monitoring and managing lung fluid levels in patients with heart failure and other chronic diseases requiring lung fluid level monitoring. The company primarily serves the healthcare industry. It was founded in 2007 and is based in Netanya, Israel.


Neteera is a sensing technology company that develops monitoring technology using signal processing and data interpretation. It develops remote contactless sensing technology intended for automotive, medical, and IoT applications. The company was founded in 2015 and is based in Jerusalem, Israel.

Acorai Logo

Acorai manufactures a device to non-invasively check the pressure inside the heart using sound, vibrations, and wave patterns. Its device helps manage heart failure and aims to reduce hospital visits. The company was founded in 2019 and is based in Stockholm, Sweden.

Donisi Health

Donisi Health is a MedTech company with a focus on aiding patients with Congestive Heart Failure (CHF) and other chronic cardiopulmonary diseases. The company offers FDA-cleared, contact-free technology that remotely detects signs of pulmonary congestion, supporting early detection of changes in lung fluid content and helping to prevent unnecessary rehospitalization. Donisi Health primarily serves the healthcare industry. It was founded in 2015 and is based in Tel Aviv, Israel.


CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.